GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » EBITDA Margin %

Zenith Capital (Zenith Capital) EBITDA Margin % : 0.00% (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zenith Capital's EBITDA for the three months ended in . 20 was $0.00 Mil. Zenith Capital's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, Zenith Capital's EBITDA margin for the quarter that ended in . 20 was 0.00%.


Zenith Capital EBITDA Margin % Historical Data

The historical data trend for Zenith Capital's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital EBITDA Margin % Chart

Zenith Capital Annual Data
Trend
EBITDA Margin %

Zenith Capital Quarterly Data
EBITDA Margin %

Competitive Comparison of Zenith Capital's EBITDA Margin %

For the Biotechnology subindustry, Zenith Capital's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Zenith Capital's EBITDA Margin % falls into.



Zenith Capital EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Zenith Capital's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Zenith Capital's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zenith Capital  (OTCPK:ZHCLF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Zenith Capital EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Zenith Capital's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (Zenith Capital) Business Description

Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines